A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) in patients with unresectable stage IV metastatic melanoma: A North Central Cancer Treatment Group Study (N0775)
- Citation:
- J Clin Oncol vol 29 (suppl) abstr 8532
- Meeting Instance:
- ASCO 2011
- Year:
- 2011
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 883
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- L. Kottschade V. Suman D. Perez R. Mcwilliams J. Kaur T. Amatruda F. Geoffroy H. Gross T. Fitch A. Jaslowski M. Kosel S. Markovic
- Networks:
- Study
- NCCTG-N0775
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: